Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.4/832 |
Resumo: | INTRODUCTION: Obesity is a chronic disease and a serious health problem that leads to increased prevalence of diabetes, hypertension, dyslipidemia and gallbladder disease. OBJECTIVE: To evaluate the efficacy of orlistat for weight loss and improved lipid profile compared to placebo in obese patients with hypercholesterolemia, treated over a period of 6 months. METHODOLOGY: In a 6-month, multicenter (10 centers in Portugal), double-blind, parallel, placebo-controlled study, 166 patients, aged 18-65 years, body mass index (BMI) > or = 27 kg/m2, LDL cholesterol > 155 mg/dl, were randomized to a reduced calorie diet (600 kcal/day deficit) plus orlistat three times a day or placebo. Exclusion criteria included triglycerides > 400 mg/dl, severe cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes under pharmacological treatment, and gastrointestinal or pancreatic disease. RESULTS: The mean difference in weight from baseline was 5.9% (5.6 kg) in the orlistat group vs. 2.3% (2.2 kg) in the placebo group. In the orlistat group 49% of patients achieved 5-10% weight loss and 8.8% achieved > 10%. The orlistat group showed a significant reduction in total and LDL cholesterol, with similar changes for HDL in both treatment groups. The frequency of gastrointestinal adverse events was slightly higher in the orlistat group than in the placebo group, leading to discontinuation in 7 patients. CONCLUSION: Treatment with orlistat plus a reduced calorie diet for 6 months achieved significant reductions in weight, BMI and lipid parameters. |
id |
RCAP_876e0b91f29a9e54619da5bd6b59a36d |
---|---|
oai_identifier_str |
oai:rihuc.huc.min-saude.pt:10400.4/832 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderadaA randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemiaHipercolesterolemiaObesidadeFármacos Anti-obesidadeEstudo ComparativoEstudo MulticêntricoEnsaio Randomizado ControladoINTRODUCTION: Obesity is a chronic disease and a serious health problem that leads to increased prevalence of diabetes, hypertension, dyslipidemia and gallbladder disease. OBJECTIVE: To evaluate the efficacy of orlistat for weight loss and improved lipid profile compared to placebo in obese patients with hypercholesterolemia, treated over a period of 6 months. METHODOLOGY: In a 6-month, multicenter (10 centers in Portugal), double-blind, parallel, placebo-controlled study, 166 patients, aged 18-65 years, body mass index (BMI) > or = 27 kg/m2, LDL cholesterol > 155 mg/dl, were randomized to a reduced calorie diet (600 kcal/day deficit) plus orlistat three times a day or placebo. Exclusion criteria included triglycerides > 400 mg/dl, severe cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes under pharmacological treatment, and gastrointestinal or pancreatic disease. RESULTS: The mean difference in weight from baseline was 5.9% (5.6 kg) in the orlistat group vs. 2.3% (2.2 kg) in the placebo group. In the orlistat group 49% of patients achieved 5-10% weight loss and 8.8% achieved > 10%. The orlistat group showed a significant reduction in total and LDL cholesterol, with similar changes for HDL in both treatment groups. The frequency of gastrointestinal adverse events was slightly higher in the orlistat group than in the placebo group, leading to discontinuation in 7 patients. CONCLUSION: Treatment with orlistat plus a reduced calorie diet for 6 months achieved significant reductions in weight, BMI and lipid parameters.Sociedade Portuguesa de CardiologiaRIHUCCastro, JJDias, TChambel, PCarvalheiro, MCorreia, LGGuerreiro, LMarques, OMedina, JLNobre, ENunes, JSPereira, MCPolónia, JPortugal, JRaimundo, ARuas, AMarques da Silva, PVasconcelos, CReis, JLGalvão Teles, A2010-11-10T12:08:55Z20092009-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/832porRev Port Cardiol. 2009 Dec;28(12):1361-74.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:22:01Zoai:rihuc.huc.min-saude.pt:10400.4/832Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:03:22.490164Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia |
title |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada |
spellingShingle |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada Castro, JJ Hipercolesterolemia Obesidade Fármacos Anti-obesidade Estudo Comparativo Estudo Multicêntrico Ensaio Randomizado Controlado |
title_short |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada |
title_full |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada |
title_fullStr |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada |
title_full_unstemmed |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada |
title_sort |
Estudo comparativo, aleatorizado, em dupla ocultação, de orlistat versus placebo , de eficácia e segurança, em doentes obesos com hipercolesterolemia ligiera a moderada |
author |
Castro, JJ |
author_facet |
Castro, JJ Dias, T Chambel, P Carvalheiro, M Correia, LG Guerreiro, L Marques, O Medina, JL Nobre, E Nunes, JS Pereira, MC Polónia, J Portugal, J Raimundo, A Ruas, A Marques da Silva, P Vasconcelos, C Reis, JL Galvão Teles, A |
author_role |
author |
author2 |
Dias, T Chambel, P Carvalheiro, M Correia, LG Guerreiro, L Marques, O Medina, JL Nobre, E Nunes, JS Pereira, MC Polónia, J Portugal, J Raimundo, A Ruas, A Marques da Silva, P Vasconcelos, C Reis, JL Galvão Teles, A |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
RIHUC |
dc.contributor.author.fl_str_mv |
Castro, JJ Dias, T Chambel, P Carvalheiro, M Correia, LG Guerreiro, L Marques, O Medina, JL Nobre, E Nunes, JS Pereira, MC Polónia, J Portugal, J Raimundo, A Ruas, A Marques da Silva, P Vasconcelos, C Reis, JL Galvão Teles, A |
dc.subject.por.fl_str_mv |
Hipercolesterolemia Obesidade Fármacos Anti-obesidade Estudo Comparativo Estudo Multicêntrico Ensaio Randomizado Controlado |
topic |
Hipercolesterolemia Obesidade Fármacos Anti-obesidade Estudo Comparativo Estudo Multicêntrico Ensaio Randomizado Controlado |
description |
INTRODUCTION: Obesity is a chronic disease and a serious health problem that leads to increased prevalence of diabetes, hypertension, dyslipidemia and gallbladder disease. OBJECTIVE: To evaluate the efficacy of orlistat for weight loss and improved lipid profile compared to placebo in obese patients with hypercholesterolemia, treated over a period of 6 months. METHODOLOGY: In a 6-month, multicenter (10 centers in Portugal), double-blind, parallel, placebo-controlled study, 166 patients, aged 18-65 years, body mass index (BMI) > or = 27 kg/m2, LDL cholesterol > 155 mg/dl, were randomized to a reduced calorie diet (600 kcal/day deficit) plus orlistat three times a day or placebo. Exclusion criteria included triglycerides > 400 mg/dl, severe cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes under pharmacological treatment, and gastrointestinal or pancreatic disease. RESULTS: The mean difference in weight from baseline was 5.9% (5.6 kg) in the orlistat group vs. 2.3% (2.2 kg) in the placebo group. In the orlistat group 49% of patients achieved 5-10% weight loss and 8.8% achieved > 10%. The orlistat group showed a significant reduction in total and LDL cholesterol, with similar changes for HDL in both treatment groups. The frequency of gastrointestinal adverse events was slightly higher in the orlistat group than in the placebo group, leading to discontinuation in 7 patients. CONCLUSION: Treatment with orlistat plus a reduced calorie diet for 6 months achieved significant reductions in weight, BMI and lipid parameters. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009 2009-01-01T00:00:00Z 2010-11-10T12:08:55Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.4/832 |
url |
http://hdl.handle.net/10400.4/832 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Rev Port Cardiol. 2009 Dec;28(12):1361-74. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Cardiologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Cardiologia |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131697617305600 |